Apogee Therapeutics, Inc.

NASDAQ:APGE

Biotechnology

Healthcare
$135.07 +1.18%

+$1.05 today

Market cap
$8.36B
Beta
0.62
P/E (TTM)
-22.7
EPS (TTM)
-$3.94
52W Low $34.34High $95.32

Volume 0.00M

Average 0.97M

APGE Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Apogee Therapeutics, Inc.NASDAQ: APGE

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue remains negative

Q2 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $408K.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $102K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$1.42M— YoY
LTMJun 2026
$408K— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
1.42M USD
Year-over-year change
—

Cost of Revenue vs competitors

How APGE compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
APGE Competitors
Cost of Revenue for APGE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$584.36M USD+63.0%+84.1%43.0%
ZLABZai Lab LimitedLTM Jun 2026$195.71M USD+21.7%+37.2%43.5%
AAPGAscentage Pharma Group InternationalFY2025CN¥131.73M CNY+352.9%+81.6%23.6%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$109.99M USD+25.2%+56.7%16.4%
CGONCG Oncology, Inc. Common stockLTM Sep 2026$12.47M USD-85.7%+576.6%202.2%
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$611K USD-99.2%——
APGEApogee Therapeutics, Inc.LTM Jun 2026$408K USD———
CNTACentessa Pharmaceuticals plcLTM Mar 2026$238.6K USD———
CELCCelcuity Inc.LTM Jun 2026$47K USD+33.3%——
IRONDisc Medicine, Inc.LTM Sep 2026$0 USD———
Peer median (excluding APGE) —+25.2%+81.6%43.0%

Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0001.42M
Gross Profit000(1.42M)
Gross Margin————
Research & Development27.79M68.42M167.87M214.71M
Selling, General & Admin2.94M24.58M49.01M70.88M
Operating Expenses30.73M93M216.87M284.18M
Depreciation & Amortization09.02M189K1.42M
EBITDA(39.79M)(74.97M)(181.94M)(254.15M)
EBITDA Margin————
Operating Income(30.73M)(93M)(216.87M)(285.6M)
Operating Margin————
Interest Income92K9.02M34.74M30.03M
Interest Expense9.15M000
Other Income / Expenses(9.06M)9.02M34.74M30.03M
Income Before Tax(39.79M)(83.99M)(182.13M)(255.57M)
Pre-Tax Margin————
Income Tax Expense0018K278K
Net Income(39.79M)(83.99M)(182.15M)(255.84M)
Net Margin————
EPS (Basic)(0.79)(1.66)(3.30)(4.22)
EPS (Diluted)(0.79)(1.66)(3.30)(4.22)
Weighted Avg Shares50.67M50.66M55.19M60.69M
Weighted Avg Shares (Diluted)50.67M50.66M55.19M60.69M

Apogee Therapeutics, Inc.

NASDAQ:APGE

Intrinsic Alpha fair value

Locked

Current Price

$135.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.